Objective: ENDEAVOR (NCT01568866) is comparing Kd with Vd in patients with RMM.The primary endpoint is PFS.Secondary endpoints include OS, ORR, peripheral n
Objective: To make a research on the prognosis factors of non-hodgkin lymphoma (NHL) cases, and discuss how to improve the prognosis as far as possible.Meth
Objective: Carfilzomib (K) is a selective proteasome inhibitor that is approved in the United States for the treatment of relapsed and refractory multiple m